Tag: Axsome mixed Phase 3 results Alzheimer’s drug

Axsome Submits Alzheimer’s Disease Drug for FDA Approval Axsome Therapeutics, a New York-based biotech company, is forging ahead with its plans to seek FDA approval for its Alzheimer’s disease treatment, AXS-05, following results from Phase...